RxDoctor Payments Data

Mati Friehling, MD

Clinical Cardiac Electrophysiology · Pittsburgh, PANPI 1376735092

Payments from drug & device makers

$12,217in general payments, 2019–2025

Across 175 payments — averaging $69.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Boston Scientific$4K
  • Biosense Webster, Inc.$2K
  • Abbott$2K
  • Impulse Dynamics (USA) Inc.$411
  • Johnson & Johnson$285
  • plus $850 from 13 others

What the payments were for

  • Consulting fees$1,70014%
  • Travel & lodging$3,04625%
  • Food & beverage$7,47161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,217 in reported general payments places this provider in the 30th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

See all clinical cardiac electrophysiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$138,740
Medicare patients
1,548
Services billed
2,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban117$113,241
XareltoRivaroxaban68$61,127
Dofetilide63$16,838
CorlanorIvabradine Hcl21$12,261
MultaqDronedarone Hcl16$11,754
Flecainide Acetate198$9,060
Propafenone Hcl53$3,678
Mexiletine Hcl29$2,766
Amiodarone Hcl87$1,471
Diltiazem 24hr Er (Cd)Diltiazem Hcl79$1,427
SotalolSotalol Hcl63$1,220
Digoxin16$830
Metoprolol Succinate75$771
Diltiazem 24hr ErDiltiazem Hcl18$358
Metoprolol Tartrate47$271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$220$113,241117 claims
Johnson & JohnsonXarelto$285$61,12768 claims
AmgenCorlanor$43$12,26121 claims
Sanofi-aventis U.S. LLCMultaq$20$11,75416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

Other clinical cardiac electrophysiology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →